<DOC>
	<DOCNO>NCT00176527</DOCNO>
	<brief_summary>RATIONALE : Isotretinoin may help prostate cancer cell become like normal cell , grow spread slowly . Interferon alfa-2b may interfere growth tumor cell . Drugs use chemotherapy , docetaxel estramustine , work different way stop growth tumor cell , either kill cell stop divide . Giving isotretinoin interferon alfa-2b together docetaxel estramustine may kill tumor cell . PURPOSE : This phase II trial study well give isotretinoin interferon alfa-2b together docetaxel estramustine work treat patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Isotretinoin , Interferon Alfa-2b , Docetaxel , Estramustine Treating Patients With Metastatic Prostate Cancer That Did Not Respond Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate , term change measurable disease prostate-specific antigen level , patient hormone-refractory metastatic prostate cancer treat isotretinoin , recombinant interferon alfa-2b , docetaxel , estramustine phosphate sodium . Secondary - Determine effect regimen bcl-2 family proteins peripheral blood mononuclear cell sample obtain patient . OUTLINE : Patients receive oral isotretinoin daily day 1-4 , recombinant interferon alfa-2b subcutaneously daily day 1-4 , oral estramustine phosphate sodium three time daily day 1-5 , docetaxel IV 1 hour day 2 . Treatment repeat every 21 day absence disease progression unacceptable toxicity . Peripheral blood mononuclear cell acquire via blood draw baseline day 2 , 3 , 4 analyze bcl-2 protein IHC electrophoresis . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Estramustine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hormonerefractory metastatic prostate cancer Patients recently withdraw treatment bicalutamide flutamide must demonstrate progression disease Measurable disease OR prostatespecific antigen level ≥ 10 ng/mL PATIENT CHARACTERISTICS : ECOG performance status 02 Estimated life expectancy ≥ 6 month Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 8 g/dL Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 50 mL/min Bilirubin normal AST , ALT , alkaline phosphatase ( AP ) must meet 1 follow criterion : AP normal AST ALT ≤ 2.5 time upper limit normal ( ULN ) AP elevate AST ALT normal No history severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No peripheral neuropathy &gt; grade 1 No concurrent active infection No concurrent major depression suicidal ideation No concurrent medical condition would preclude study participation No known HIV positivity Fertile patient must use effective contraception 10 week completion study therapy PRIOR CONCURRENT THERAPY : Recovered prior surgery radiotherapy No prior chemotherapy , retinoids , interferon therapy More 4 week since prior flutamide More 6 week since prior bicalutamide</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>